Stem definition | Drug id | CAS RN |
---|---|---|
calcium channel blockers, diltiazem derivatives | 897 | 42399-41-7 |
Dose | Unit | Route |
---|---|---|
0.24 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 2 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 19.30 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 38 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 4.10 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 13 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.18 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 5.60 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Nov. 5, 1982 | FDA | VALEANT INTL |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Completed suicide | 704.44 | 10.25 | 1155 | 94986 | 144765 | 46445156 |
Atrial fibrillation | 584.13 | 10.25 | 881 | 95260 | 102709 | 46487212 |
Cardiac failure congestive | 272.75 | 10.25 | 591 | 95550 | 91159 | 46498762 |
Bradycardia | 224.96 | 10.25 | 451 | 95690 | 65847 | 46524074 |
Rheumatoid arthritis | 202.62 | 10.25 | 122 | 96019 | 240093 | 46349828 |
Hypotension | 192.59 | 10.25 | 967 | 95174 | 231622 | 46358299 |
Off label use | 190.20 | 10.25 | 306 | 95835 | 379535 | 46210386 |
Drug ineffective | 189.80 | 10.25 | 738 | 95403 | 677100 | 45912821 |
Maternal exposure during pregnancy | 151.55 | 10.25 | 17 | 96124 | 102532 | 46487389 |
Dyspnoea | 137.47 | 10.25 | 1642 | 94499 | 513906 | 46076015 |
Exposure during pregnancy | 130.89 | 10.25 | 31 | 96110 | 108181 | 46481740 |
Nodal rhythm | 113.17 | 10.25 | 60 | 96081 | 1665 | 46588256 |
Sedation complication | 112.13 | 10.25 | 78 | 96063 | 3567 | 46586354 |
Creatinine renal clearance decreased | 109.13 | 10.25 | 100 | 96041 | 6820 | 46583101 |
Toxicity to various agents | 107.33 | 10.25 | 775 | 95366 | 210991 | 46378930 |
Treatment failure | 102.54 | 10.25 | 32 | 96109 | 93055 | 46496866 |
Neutropenia | 99.50 | 10.25 | 89 | 96052 | 143115 | 46446806 |
Cardiac arrest | 92.34 | 10.25 | 400 | 95741 | 89999 | 46499922 |
Atrioventricular block complete | 91.72 | 10.25 | 95 | 96046 | 7532 | 46582389 |
Nerve injury | 87.36 | 10.25 | 93 | 96048 | 7612 | 46582309 |
Febrile neutropenia | 84.03 | 10.25 | 45 | 96096 | 94582 | 46495339 |
Orthostatic hypotension | 83.86 | 10.25 | 168 | 95973 | 24490 | 46565431 |
Dyspnoea exertional | 81.19 | 10.25 | 258 | 95883 | 50031 | 46539890 |
Fluid retention | 77.10 | 10.25 | 256 | 95885 | 50790 | 46539131 |
Synovitis | 76.85 | 10.25 | 16 | 96125 | 61059 | 46528862 |
Atrioventricular block second degree | 76.26 | 10.25 | 63 | 96078 | 3736 | 46586185 |
Heart rate increased | 75.65 | 10.25 | 330 | 95811 | 74461 | 46515460 |
Chronic obstructive pulmonary disease | 74.90 | 10.25 | 275 | 95866 | 57358 | 46532563 |
Poisoning | 73.01 | 10.25 | 115 | 96026 | 13879 | 46576042 |
Gastrointestinal haemorrhage | 71.22 | 10.25 | 332 | 95809 | 77041 | 46512880 |
Pemphigus | 70.81 | 10.25 | 6 | 96135 | 45268 | 46544653 |
International normalised ratio increased | 68.92 | 10.25 | 233 | 95908 | 46650 | 46543271 |
Sinus bradycardia | 67.44 | 10.25 | 110 | 96031 | 13672 | 46576249 |
Chest pain | 67.29 | 10.25 | 605 | 95536 | 175719 | 46414202 |
Oedema peripheral | 65.62 | 10.25 | 557 | 95584 | 159149 | 46430772 |
Atrioventricular block first degree | 63.74 | 10.25 | 71 | 96070 | 6115 | 46583806 |
Therapeutic product effect incomplete | 62.59 | 10.25 | 42 | 96099 | 78111 | 46511810 |
Cardiogenic shock | 62.27 | 10.25 | 117 | 96024 | 16267 | 46573654 |
Drug intolerance | 58.10 | 10.25 | 136 | 96005 | 146913 | 46443008 |
Labile blood pressure | 56.06 | 10.25 | 38 | 96103 | 1665 | 46588256 |
Product use issue | 55.38 | 10.25 | 68 | 96073 | 94576 | 46495345 |
Contraindicated product administered | 55.12 | 10.25 | 50 | 96091 | 79897 | 46510024 |
Systemic lupus erythematosus | 54.98 | 10.25 | 33 | 96108 | 65147 | 46524774 |
Pulmonary congestion | 54.16 | 10.25 | 104 | 96037 | 14695 | 46575226 |
Abortion spontaneous | 53.75 | 10.25 | 12 | 96129 | 43634 | 46546287 |
Rash | 53.57 | 10.25 | 473 | 95668 | 356039 | 46233882 |
Leukopenia | 53.04 | 10.25 | 38 | 96103 | 68305 | 46521616 |
Therapeutic product effect decreased | 50.85 | 10.25 | 57 | 96084 | 82544 | 46507377 |
Injection site erythema | 50.77 | 10.25 | 47 | 96094 | 74380 | 46515541 |
Heart rate decreased | 50.50 | 10.25 | 162 | 95979 | 31561 | 46558360 |
Atrial flutter | 48.86 | 10.25 | 76 | 96065 | 9072 | 46580849 |
Alopecia | 48.21 | 10.25 | 172 | 95969 | 162242 | 46427679 |
Hand deformity | 47.98 | 10.25 | 7 | 96134 | 34567 | 46555354 |
Pulmonary arterial hypertension | 47.42 | 10.25 | 139 | 96002 | 25789 | 46564132 |
Fall | 46.60 | 10.25 | 943 | 95198 | 328154 | 46261767 |
Pneumonia | 46.45 | 10.25 | 1057 | 95084 | 375263 | 46214658 |
Dizziness | 46.09 | 10.25 | 969 | 95172 | 339445 | 46250476 |
Product use in unapproved indication | 45.67 | 10.25 | 72 | 96069 | 90201 | 46499720 |
Product complaint | 45.47 | 10.25 | 86 | 96055 | 12015 | 46577906 |
Malignant neoplasm progression | 44.28 | 10.25 | 41 | 96100 | 64885 | 46525036 |
Cardiac disorder | 43.17 | 10.25 | 192 | 95949 | 43666 | 46546255 |
Suspected suicide | 42.13 | 10.25 | 50 | 96091 | 4611 | 46585310 |
Coronary artery disease | 42.12 | 10.25 | 159 | 95982 | 33593 | 46556328 |
Blood calcium decreased | 42.04 | 10.25 | 97 | 96044 | 15576 | 46574345 |
Palpitations | 40.55 | 10.25 | 335 | 95806 | 94924 | 46494997 |
Pericardial haemorrhage | 40.40 | 10.25 | 30 | 96111 | 1521 | 46588400 |
Supraventricular tachycardia | 39.94 | 10.25 | 86 | 96055 | 13184 | 46576737 |
Medication error | 39.72 | 10.25 | 147 | 95994 | 30764 | 46559157 |
Asthenia | 39.68 | 10.25 | 878 | 95263 | 310197 | 46279724 |
Pyrexia | 39.63 | 10.25 | 494 | 95647 | 348308 | 46241613 |
Renal failure | 39.38 | 10.25 | 382 | 95759 | 113212 | 46476709 |
Acute generalised exanthematous pustulosis | 39.32 | 10.25 | 70 | 96071 | 9335 | 46580586 |
Sedation | 39.23 | 10.25 | 120 | 96021 | 22790 | 46567131 |
Hepatic enzyme increased | 37.02 | 10.25 | 70 | 96071 | 81717 | 46508204 |
Hypoxia | 36.88 | 10.25 | 207 | 95934 | 51631 | 46538290 |
Foetal exposure during pregnancy | 36.77 | 10.25 | 9 | 96132 | 30738 | 46559183 |
Angina pectoris | 36.67 | 10.25 | 130 | 96011 | 26645 | 46563276 |
Pulmonary hypertension | 36.51 | 10.25 | 159 | 95982 | 35834 | 46554087 |
Respiratory arrest | 36.32 | 10.25 | 152 | 95989 | 33664 | 46556257 |
Hyperkalaemia | 35.10 | 10.25 | 201 | 95940 | 50508 | 46539413 |
Drug interaction | 34.58 | 10.25 | 599 | 95542 | 202495 | 46387426 |
White blood cell count decreased | 33.86 | 10.25 | 118 | 96023 | 112113 | 46477808 |
Nodal arrhythmia | 33.83 | 10.25 | 25 | 96116 | 1258 | 46588663 |
Inhibitory drug interaction | 33.76 | 10.25 | 30 | 96111 | 1965 | 46587956 |
Joint swelling | 33.74 | 10.25 | 202 | 95939 | 165871 | 46424050 |
Presyncope | 33.72 | 10.25 | 119 | 96022 | 24335 | 46565586 |
Arthropathy | 33.70 | 10.25 | 78 | 96063 | 84622 | 46505299 |
Infusion related reaction | 33.59 | 10.25 | 102 | 96039 | 101106 | 46488815 |
Pain in jaw | 33.36 | 10.25 | 162 | 95979 | 38210 | 46551711 |
Intentional self-injury | 33.29 | 10.25 | 5 | 96136 | 24161 | 46565760 |
Balance disorder | 33.08 | 10.25 | 237 | 95904 | 64284 | 46525637 |
Musculoskeletal stiffness | 33.07 | 10.25 | 98 | 96043 | 97895 | 46492026 |
Blood pressure systolic increased | 32.98 | 10.25 | 132 | 96009 | 28655 | 46561266 |
C-reactive protein abnormal | 32.77 | 10.25 | 3 | 96138 | 21267 | 46568654 |
Nephrolithiasis | 32.76 | 10.25 | 145 | 95996 | 32906 | 46557015 |
Thrombocytopenia | 32.49 | 10.25 | 142 | 95999 | 126439 | 46463482 |
Oedema | 32.46 | 10.25 | 243 | 95898 | 66828 | 46523093 |
Torsade de pointes | 32.35 | 10.25 | 75 | 96066 | 12079 | 46577842 |
Pulseless electrical activity | 32.12 | 10.25 | 55 | 96086 | 7112 | 46582809 |
Injection site pain | 32.10 | 10.25 | 113 | 96028 | 107039 | 46482882 |
Premature delivery | 31.74 | 10.25 | 4 | 96137 | 22065 | 46567856 |
Bezoar | 31.59 | 10.25 | 25 | 96116 | 1394 | 46588527 |
Arthralgia | 31.12 | 10.25 | 546 | 95595 | 364057 | 46225864 |
Atrioventricular block | 30.17 | 10.25 | 52 | 96089 | 6759 | 46583162 |
Respiratory tract congestion | 29.93 | 10.25 | 75 | 96066 | 12689 | 46577232 |
Body tinea | 28.74 | 10.25 | 20 | 96121 | 915 | 46589006 |
Pulmonary oedema | 28.72 | 10.25 | 192 | 95949 | 50913 | 46539008 |
Pregnancy | 28.69 | 10.25 | 10 | 96131 | 27127 | 46562794 |
Myocardial infarction | 28.59 | 10.25 | 317 | 95824 | 97211 | 46492710 |
Suicidal ideation | 28.48 | 10.25 | 45 | 96096 | 56337 | 46533584 |
Glossodynia | 27.98 | 10.25 | 30 | 96111 | 44343 | 46545578 |
General physical health deterioration | 27.84 | 10.25 | 133 | 96008 | 115636 | 46474285 |
Neutrophil count decreased | 26.68 | 10.25 | 30 | 96111 | 43396 | 46546525 |
Ventricular tachycardia | 26.42 | 10.25 | 86 | 96055 | 16881 | 46573040 |
Bunion operation | 26.33 | 10.25 | 18 | 96123 | 800 | 46589121 |
Product residue present | 26.17 | 10.25 | 36 | 96105 | 3846 | 46586075 |
Pancytopenia | 25.94 | 10.25 | 89 | 96052 | 84969 | 46504952 |
Intentional product use issue | 25.84 | 10.25 | 43 | 96098 | 52737 | 46537184 |
Blood pressure diastolic decreased | 25.81 | 10.25 | 76 | 96065 | 14135 | 46575786 |
Cognitive disorder | 25.39 | 10.25 | 146 | 95995 | 36737 | 46553184 |
Erythromelalgia | 25.28 | 10.25 | 10 | 96131 | 137 | 46589784 |
Transfusion | 25.22 | 10.25 | 72 | 96069 | 13159 | 46576762 |
Depressed level of consciousness | 25.12 | 10.25 | 176 | 95965 | 47393 | 46542528 |
Injection site pruritus | 24.92 | 10.25 | 27 | 96114 | 39716 | 46550205 |
Arrhythmia | 24.69 | 10.25 | 139 | 96002 | 34702 | 46555219 |
Alveolitis | 24.45 | 10.25 | 28 | 96113 | 2485 | 46587436 |
Seizure | 24.29 | 10.25 | 151 | 95990 | 122903 | 46467018 |
Sinus arrhythmia | 24.11 | 10.25 | 21 | 96120 | 1339 | 46588582 |
Fluid overload | 23.79 | 10.25 | 115 | 96026 | 27070 | 46562851 |
Cardioactive drug level increased | 23.60 | 10.25 | 25 | 96116 | 2034 | 46587887 |
Gouty tophus | 23.54 | 10.25 | 10 | 96131 | 166 | 46589755 |
Sinus arrest | 23.45 | 10.25 | 23 | 96118 | 1708 | 46588213 |
Hepatic ischaemia | 23.41 | 10.25 | 14 | 96127 | 492 | 46589429 |
Arteriovenous fistula occlusion | 23.17 | 10.25 | 12 | 96129 | 317 | 46589604 |
Colon gangrene | 23.01 | 10.25 | 5 | 96136 | 4 | 46589917 |
Death | 22.99 | 10.25 | 876 | 95265 | 334672 | 46255249 |
Muscle relaxant therapy | 22.97 | 10.25 | 9 | 96132 | 120 | 46589801 |
Mucosal inflammation | 22.79 | 10.25 | 28 | 96113 | 38948 | 46550973 |
Erythrodermic psoriasis | 22.72 | 10.25 | 17 | 96124 | 872 | 46589049 |
Syncope | 22.71 | 10.25 | 322 | 95819 | 104481 | 46485440 |
Blue toe syndrome | 22.31 | 10.25 | 12 | 96129 | 343 | 46589578 |
Premature baby | 22.26 | 10.25 | 5 | 96136 | 18107 | 46571814 |
Drug hypersensitivity | 21.78 | 10.25 | 362 | 95779 | 243463 | 46346458 |
Bladder prolapse | 21.71 | 10.25 | 23 | 96118 | 1871 | 46588050 |
C-reactive protein increased | 21.69 | 10.25 | 56 | 96085 | 58534 | 46531387 |
Vasoplegia syndrome | 21.69 | 10.25 | 18 | 96123 | 1074 | 46588847 |
Rectal prolapse | 21.53 | 10.25 | 21 | 96120 | 1549 | 46588372 |
Injection site swelling | 21.51 | 10.25 | 31 | 96110 | 40296 | 46549625 |
Epilepsy | 21.48 | 10.25 | 11 | 96130 | 23727 | 46566194 |
Blood pressure inadequately controlled | 21.33 | 10.25 | 35 | 96106 | 4371 | 46585550 |
Heart rate irregular | 21.09 | 10.25 | 85 | 96056 | 18506 | 46571415 |
Rectal haemorrhage | 21.06 | 10.25 | 143 | 95998 | 38112 | 46551809 |
BRASH syndrome | 21.03 | 10.25 | 8 | 96133 | 98 | 46589823 |
Hospitalisation | 20.90 | 10.25 | 211 | 95930 | 63174 | 46526747 |
Cardioversion | 20.85 | 10.25 | 18 | 96123 | 1134 | 46588787 |
Nephroangiosclerosis | 20.83 | 10.25 | 9 | 96132 | 156 | 46589765 |
Unevaluable event | 20.50 | 10.25 | 164 | 95977 | 46011 | 46543910 |
Depression | 20.37 | 10.25 | 238 | 95903 | 169866 | 46420055 |
Psoriasis | 20.27 | 10.25 | 88 | 96053 | 78516 | 46511405 |
Cerebellar syndrome | 20.22 | 10.25 | 30 | 96111 | 3435 | 46586486 |
Cardiac pacemaker insertion | 20.13 | 10.25 | 31 | 96110 | 3668 | 46586253 |
Coagulopathy | 19.74 | 10.25 | 83 | 96058 | 18416 | 46571505 |
Renal pain | 19.52 | 10.25 | 38 | 96103 | 5423 | 46584498 |
Status epilepticus | 19.01 | 10.25 | 3 | 96138 | 13976 | 46575945 |
Posterior reversible encephalopathy syndrome | 18.97 | 10.25 | 4 | 96137 | 15137 | 46574784 |
Bone marrow failure | 18.77 | 10.25 | 20 | 96121 | 29649 | 46560272 |
Thermal burn | 18.74 | 10.25 | 35 | 96106 | 4842 | 46585079 |
Prinzmetal angina | 18.32 | 10.25 | 14 | 96127 | 741 | 46589180 |
Stent placement | 18.24 | 10.25 | 29 | 96112 | 3527 | 46586394 |
Multiple sclerosis relapse | 18.23 | 10.25 | 37 | 96104 | 42088 | 46547833 |
Stomatitis | 17.89 | 10.25 | 76 | 96065 | 68221 | 46521700 |
Cerebrovascular accident | 17.89 | 10.25 | 300 | 95841 | 100739 | 46489182 |
Inappropriate schedule of product administration | 17.87 | 10.25 | 71 | 96070 | 64942 | 46524979 |
Anuria | 17.85 | 10.25 | 58 | 96083 | 11373 | 46578548 |
Injection site reaction | 17.51 | 10.25 | 46 | 96095 | 47803 | 46542118 |
Impaired quality of life | 17.41 | 10.25 | 27 | 96114 | 3215 | 46586706 |
Drug resistance | 17.35 | 10.25 | 7 | 96134 | 17361 | 46572560 |
Hepatorenal syndrome | 17.35 | 10.25 | 20 | 96121 | 1788 | 46588133 |
Sleep disorder | 17.11 | 10.25 | 45 | 96096 | 46750 | 46543171 |
Stupor | 17.09 | 10.25 | 28 | 96113 | 3492 | 46586429 |
Cytomegalovirus infection | 17.04 | 10.25 | 8 | 96133 | 18136 | 46571785 |
Fear of eating | 17.02 | 10.25 | 10 | 96131 | 340 | 46589581 |
Disease progression | 17.01 | 10.25 | 114 | 96027 | 91186 | 46498735 |
Oxygen therapy | 16.91 | 10.25 | 20 | 96121 | 1837 | 46588084 |
Blood pressure increased | 16.88 | 10.25 | 360 | 95781 | 126306 | 46463615 |
Blood loss anaemia | 16.73 | 10.25 | 47 | 96094 | 8510 | 46581411 |
Limb injury | 16.70 | 10.25 | 81 | 96060 | 19093 | 46570828 |
Myopathy | 16.61 | 10.25 | 48 | 96093 | 8833 | 46581088 |
Extrasystoles | 16.34 | 10.25 | 33 | 96108 | 4836 | 46585085 |
Peak expiratory flow rate abnormal | 16.33 | 10.25 | 7 | 96134 | 119 | 46589802 |
Metabolic acidosis | 16.28 | 10.25 | 136 | 96005 | 38644 | 46551277 |
Drug-induced liver injury | 16.16 | 10.25 | 17 | 96124 | 25351 | 46564570 |
Electrocardiogram QT shortened | 16.11 | 10.25 | 7 | 96134 | 123 | 46589798 |
Leukaemoid reaction | 16.11 | 10.25 | 8 | 96133 | 193 | 46589728 |
Urticaria | 16.10 | 10.25 | 160 | 95981 | 117732 | 46472189 |
Aggression | 15.94 | 10.25 | 14 | 96127 | 22730 | 46567191 |
Catheter site erythema | 15.83 | 10.25 | 29 | 96112 | 3954 | 46585967 |
Cardiac ablation | 15.71 | 10.25 | 16 | 96125 | 1243 | 46588678 |
Psoriatic arthropathy | 15.71 | 10.25 | 32 | 96109 | 36347 | 46553574 |
Distributive shock | 15.68 | 10.25 | 11 | 96130 | 510 | 46589411 |
Acute lung injury | 15.59 | 10.25 | 16 | 96125 | 1255 | 46588666 |
Sinus node dysfunction | 15.52 | 10.25 | 30 | 96111 | 4259 | 46585662 |
Sopor | 15.41 | 10.25 | 11 | 96130 | 19817 | 46570104 |
Forced expiratory volume decreased | 15.27 | 10.25 | 33 | 96108 | 5071 | 46584850 |
Atrioventricular dissociation | 15.25 | 10.25 | 8 | 96133 | 217 | 46589704 |
Heart rate abnormal | 15.19 | 10.25 | 26 | 96115 | 3361 | 46586560 |
Catheter site haemorrhage | 15.16 | 10.25 | 23 | 96118 | 2686 | 46587235 |
Histoplasmosis | 15.06 | 10.25 | 18 | 96123 | 1672 | 46588249 |
Red blood cell sedimentation rate increased | 14.97 | 10.25 | 15 | 96126 | 22874 | 46567047 |
Productive cough | 14.92 | 10.25 | 165 | 95976 | 50550 | 46539371 |
Carbon dioxide increased | 14.80 | 10.25 | 15 | 96126 | 1159 | 46588762 |
Exposure via ingestion | 14.75 | 10.25 | 26 | 96115 | 3441 | 46586480 |
Pain | 14.70 | 10.25 | 818 | 95323 | 476130 | 46113791 |
Activated partial thromboplastin time prolonged | 14.63 | 10.25 | 39 | 96102 | 6850 | 46583071 |
Dialysis | 14.61 | 10.25 | 50 | 96091 | 10066 | 46579855 |
Hepatotoxicity | 14.59 | 10.25 | 18 | 96123 | 24991 | 46564930 |
Pulmonary embolism | 14.56 | 10.25 | 148 | 95993 | 108437 | 46481484 |
Anion gap abnormal | 14.52 | 10.25 | 9 | 96132 | 338 | 46589583 |
Infection susceptibility increased | 14.38 | 10.25 | 20 | 96121 | 2159 | 46587762 |
Respiratory rate increased | 14.38 | 10.25 | 54 | 96087 | 11379 | 46578542 |
Disturbance in attention | 14.28 | 10.25 | 27 | 96114 | 31533 | 46558388 |
Pericarditis | 14.19 | 10.25 | 17 | 96124 | 23910 | 46566011 |
Lower gastrointestinal haemorrhage | 14.11 | 10.25 | 40 | 96101 | 7280 | 46582641 |
Cardiac monitoring | 13.97 | 10.25 | 4 | 96137 | 18 | 46589903 |
Intra-abdominal haematoma | 13.93 | 10.25 | 17 | 96124 | 1614 | 46588307 |
Poor quality sleep | 13.69 | 10.25 | 65 | 96076 | 15188 | 46574733 |
Hypertrophic cardiomyopathy | 13.68 | 10.25 | 15 | 96126 | 1269 | 46588652 |
Humidity intolerance | 13.68 | 10.25 | 9 | 96132 | 375 | 46589546 |
Total lung capacity decreased | 13.67 | 10.25 | 14 | 96127 | 1095 | 46588826 |
Oxygen saturation decreased | 13.60 | 10.25 | 209 | 95932 | 68955 | 46520966 |
Unresponsive to stimuli | 13.59 | 10.25 | 113 | 96028 | 32061 | 46557860 |
Inflammation | 13.58 | 10.25 | 53 | 96088 | 48728 | 46541193 |
Renal necrosis | 13.55 | 10.25 | 5 | 96136 | 56 | 46589865 |
Nasal congestion | 13.46 | 10.25 | 155 | 95986 | 47958 | 46541963 |
Acute myocardial infarction | 13.42 | 10.25 | 112 | 96029 | 31812 | 46558109 |
Wrong technique in product usage process | 13.38 | 10.25 | 62 | 96079 | 54360 | 46535561 |
Injection site urticaria | 13.37 | 10.25 | 4 | 96137 | 11963 | 46577958 |
Anaphylactic reaction | 13.36 | 10.25 | 60 | 96081 | 53052 | 46536869 |
Bundle branch block left | 13.36 | 10.25 | 36 | 96105 | 6363 | 46583558 |
Arrhythmogenic right ventricular dysplasia | 13.31 | 10.25 | 4 | 96137 | 22 | 46589899 |
Sebaceous gland infection | 13.29 | 10.25 | 6 | 96135 | 116 | 46589805 |
Acute myeloid leukaemia | 13.28 | 10.25 | 8 | 96133 | 15770 | 46574151 |
Sinoatrial block | 13.25 | 10.25 | 12 | 96129 | 806 | 46589115 |
Plasma cell myeloma | 13.25 | 10.25 | 47 | 96094 | 44431 | 46545490 |
Incision site haemorrhage | 13.24 | 10.25 | 10 | 96131 | 520 | 46589401 |
Caesarean section | 13.18 | 10.25 | 9 | 96132 | 16594 | 46573327 |
Wound | 12.90 | 10.25 | 45 | 96096 | 42757 | 46547164 |
Injection site inflammation | 12.85 | 10.25 | 23 | 96118 | 3079 | 46586842 |
Haemodialysis | 12.83 | 10.25 | 45 | 96096 | 9172 | 46580749 |
Discomfort | 12.80 | 10.25 | 51 | 96090 | 46619 | 46543302 |
Liver disorder | 12.74 | 10.25 | 37 | 96104 | 37209 | 46552712 |
Brain natriuretic peptide increased | 12.71 | 10.25 | 29 | 96112 | 4621 | 46585300 |
Arteriospasm coronary | 12.70 | 10.25 | 25 | 96116 | 3596 | 46586325 |
Osteonecrosis of jaw | 12.64 | 10.25 | 33 | 96108 | 34369 | 46555552 |
Rhabdomyolysis | 12.63 | 10.25 | 137 | 96004 | 41772 | 46548149 |
Metastases to liver | 12.62 | 10.25 | 13 | 96128 | 19572 | 46570349 |
Muscle spasticity | 12.47 | 10.25 | 4 | 96137 | 11436 | 46578485 |
Hypochromic anaemia | 12.32 | 10.25 | 15 | 96126 | 1420 | 46588501 |
Metastases to central nervous system | 12.09 | 10.25 | 4 | 96137 | 11217 | 46578704 |
Bladder disorder | 12.05 | 10.25 | 37 | 96104 | 7041 | 46582880 |
Injection site rash | 11.99 | 10.25 | 9 | 96132 | 15804 | 46574117 |
Exercise tolerance decreased | 11.91 | 10.25 | 28 | 96113 | 4549 | 46585372 |
Duodenal polyp | 11.88 | 10.25 | 5 | 96136 | 81 | 46589840 |
Migraine | 11.79 | 10.25 | 90 | 96051 | 69936 | 46519985 |
Erythema | 11.78 | 10.25 | 215 | 95926 | 142605 | 46447316 |
Night sweats | 11.74 | 10.25 | 24 | 96117 | 27226 | 46562695 |
No adverse event | 11.71 | 10.25 | 34 | 96107 | 34197 | 46555724 |
Bronchitis | 11.58 | 10.25 | 293 | 95848 | 105686 | 46484235 |
Blister | 11.48 | 10.25 | 50 | 96091 | 44581 | 46545340 |
Accidental exposure to product | 11.45 | 10.25 | 16 | 96125 | 21065 | 46568856 |
Abnormal behaviour | 11.42 | 10.25 | 16 | 96125 | 21042 | 46568879 |
Catheter site discharge | 11.40 | 10.25 | 17 | 96124 | 1955 | 46587966 |
Upper gastrointestinal haemorrhage | 11.35 | 10.25 | 66 | 96075 | 16672 | 46573249 |
Electrocardiogram QRS complex shortened | 11.34 | 10.25 | 8 | 96133 | 374 | 46589547 |
Mitral valve incompetence | 11.30 | 10.25 | 72 | 96069 | 18780 | 46571141 |
Fibrous histiocytoma | 11.26 | 10.25 | 9 | 96132 | 509 | 46589412 |
Ill-defined disorder | 11.24 | 10.25 | 24 | 96117 | 26803 | 46563118 |
Mental status changes | 11.24 | 10.25 | 124 | 96017 | 37964 | 46551957 |
CREST syndrome | 11.21 | 10.25 | 8 | 96133 | 381 | 46589540 |
Electrocardiogram U wave present | 11.20 | 10.25 | 5 | 96136 | 94 | 46589827 |
Asthma | 11.18 | 10.25 | 257 | 95884 | 91285 | 46498636 |
Pneumocystis jirovecii pneumonia | 11.16 | 10.25 | 9 | 96132 | 15239 | 46574682 |
Polyneuropathy | 11.14 | 10.25 | 5 | 96136 | 11639 | 46578282 |
Ventricular fibrillation | 11.06 | 10.25 | 50 | 96091 | 11446 | 46578475 |
Catheter site inflammation | 11.06 | 10.25 | 10 | 96131 | 670 | 46589251 |
Retroperitoneal haemorrhage | 11.00 | 10.25 | 20 | 96121 | 2710 | 46587211 |
Brain oedema | 10.97 | 10.25 | 6 | 96135 | 12472 | 46577449 |
Blood pressure decreased | 10.96 | 10.25 | 172 | 95969 | 56987 | 46532934 |
Metastases to bone | 10.81 | 10.25 | 12 | 96129 | 17464 | 46572457 |
Contusion | 10.81 | 10.25 | 246 | 95895 | 87241 | 46502680 |
Coronary artery occlusion | 10.80 | 10.25 | 39 | 96102 | 8063 | 46581858 |
Hyperbilirubinaemia | 10.77 | 10.25 | 4 | 96137 | 10434 | 46579487 |
Intestinal ischaemia | 10.69 | 10.25 | 35 | 96106 | 6890 | 46583031 |
Cough | 10.68 | 10.25 | 578 | 95563 | 229671 | 46360250 |
Seasonal allergy | 10.67 | 10.25 | 55 | 96086 | 13279 | 46576642 |
Palmar-plantar erythrodysaesthesia syndrome | 10.63 | 10.25 | 16 | 96125 | 20435 | 46569486 |
Live birth | 10.59 | 10.25 | 4 | 96137 | 10326 | 46579595 |
Atrial appendage closure | 10.57 | 10.25 | 3 | 96138 | 13 | 46589908 |
Blood count abnormal | 10.54 | 10.25 | 68 | 96073 | 17810 | 46572111 |
Aortic stenosis | 10.54 | 10.25 | 26 | 96115 | 4356 | 46585565 |
Multiple sclerosis | 10.54 | 10.25 | 22 | 96119 | 24769 | 46565152 |
Fracture | 10.54 | 10.25 | 11 | 96130 | 16460 | 46573461 |
Hepatic haematoma | 10.49 | 10.25 | 8 | 96133 | 422 | 46589499 |
Malignant melanoma | 10.43 | 10.25 | 4 | 96137 | 10230 | 46579691 |
Condition aggravated | 10.39 | 10.25 | 406 | 95735 | 244646 | 46345275 |
Jaundice | 10.35 | 10.25 | 28 | 96113 | 28817 | 46561104 |
Renal injury | 10.33 | 10.25 | 43 | 96098 | 9498 | 46580423 |
Gastrointestinal disorder | 10.30 | 10.25 | 76 | 96065 | 59500 | 46530421 |
Enlarged uvula | 10.28 | 10.25 | 5 | 96136 | 115 | 46589806 |
Gravitational oedema | 10.27 | 10.25 | 12 | 96129 | 1088 | 46588833 |
Orthopnoea | 10.25 | 10.25 | 31 | 96110 | 5849 | 46584072 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Bradycardia | 390.35 | 10.59 | 556 | 57933 | 64970 | 29829019 |
Atrial fibrillation | 316.65 | 10.59 | 670 | 57819 | 107454 | 29786535 |
Completed suicide | 290.64 | 10.59 | 616 | 57873 | 98876 | 29795113 |
Cardiac failure congestive | 143.92 | 10.59 | 426 | 58063 | 83981 | 29810008 |
Hypotension | 135.33 | 10.59 | 758 | 57731 | 199807 | 29694182 |
Off label use | 134.63 | 10.59 | 174 | 58315 | 249116 | 29644873 |
Cardiac arrest | 86.58 | 10.59 | 385 | 58104 | 92465 | 29801524 |
Febrile neutropenia | 61.07 | 10.59 | 71 | 58418 | 106622 | 29787367 |
Atrial flutter | 60.83 | 10.59 | 104 | 58385 | 14177 | 29879812 |
Dyspnoea | 59.76 | 10.59 | 947 | 57542 | 332348 | 29561641 |
Drug ineffective | 59.62 | 10.59 | 405 | 58084 | 339982 | 29554007 |
International normalised ratio increased | 58.02 | 10.59 | 215 | 58274 | 47524 | 29846465 |
Atrioventricular block complete | 56.42 | 10.59 | 76 | 58413 | 8401 | 29885588 |
Atrioventricular block | 54.23 | 10.59 | 69 | 58420 | 7213 | 29886776 |
Myocardial infarction | 50.88 | 10.59 | 419 | 58070 | 125206 | 29768783 |
Pyrexia | 46.84 | 10.59 | 360 | 58129 | 294129 | 29599860 |
Product use in unapproved indication | 46.68 | 10.59 | 45 | 58444 | 73648 | 29820341 |
Dizziness | 43.18 | 10.59 | 575 | 57914 | 194334 | 29699655 |
Chronic obstructive pulmonary disease | 41.98 | 10.59 | 190 | 58299 | 45936 | 29848053 |
Incision site pain | 41.28 | 10.59 | 33 | 58456 | 1971 | 29892018 |
Poisoning | 40.93 | 10.59 | 77 | 58412 | 11305 | 29882684 |
Prinzmetal angina | 39.80 | 10.59 | 24 | 58465 | 905 | 29893084 |
Atrioventricular block first degree | 37.86 | 10.59 | 51 | 58438 | 5637 | 29888352 |
Syncope | 36.96 | 10.59 | 288 | 58201 | 84615 | 29809374 |
Nodal arrhythmia | 36.35 | 10.59 | 22 | 58467 | 835 | 29893154 |
Neutropenia | 36.26 | 10.59 | 129 | 58360 | 128411 | 29765578 |
Drug interaction | 35.59 | 10.59 | 567 | 57922 | 199001 | 29694988 |
Arterial spasm | 34.71 | 10.59 | 12 | 58477 | 116 | 29893873 |
Gastrointestinal haemorrhage | 34.11 | 10.59 | 279 | 58210 | 83167 | 29810822 |
Coronary artery disease | 32.75 | 10.59 | 187 | 58302 | 49525 | 29844464 |
Nodal rhythm | 32.71 | 10.59 | 25 | 58464 | 1398 | 29892591 |
Cardioplegia | 31.44 | 10.59 | 6 | 58483 | 0 | 29893989 |
Chest pain | 30.71 | 10.59 | 358 | 58131 | 117269 | 29776720 |
Exposure via ingestion | 30.06 | 10.59 | 31 | 58458 | 2580 | 29891409 |
Cardiogenic shock | 29.52 | 10.59 | 86 | 58403 | 16775 | 29877214 |
Oedema peripheral | 29.38 | 10.59 | 326 | 58163 | 105506 | 29788483 |
Angina unstable | 28.88 | 10.59 | 70 | 58419 | 12240 | 29881749 |
Tetany | 28.28 | 10.59 | 18 | 58471 | 748 | 29893241 |
Heart rate decreased | 27.56 | 10.59 | 97 | 58392 | 20897 | 29873092 |
Angina pectoris | 26.40 | 10.59 | 121 | 58368 | 29397 | 29864592 |
Red blood cells urine positive | 25.83 | 10.59 | 23 | 58466 | 1594 | 29892395 |
Serotonin syndrome | 24.58 | 10.59 | 3 | 58486 | 17888 | 29876101 |
Suspected suicide | 23.61 | 10.59 | 30 | 58459 | 3131 | 29890858 |
Medication error | 23.44 | 10.59 | 92 | 58397 | 20880 | 29873109 |
General physical health deterioration | 23.32 | 10.59 | 108 | 58381 | 99836 | 29794153 |
Pancytopenia | 22.88 | 10.59 | 87 | 58402 | 84965 | 29809024 |
Blood glucose increased | 22.63 | 10.59 | 201 | 58288 | 61329 | 29832660 |
Fluid retention | 22.01 | 10.59 | 102 | 58387 | 24896 | 29869093 |
Pulmonary arterial hypertension | 21.93 | 10.59 | 53 | 58436 | 9248 | 29884741 |
Product use issue | 21.88 | 10.59 | 35 | 58454 | 45981 | 29848008 |
Influenza virus test positive | 21.02 | 10.59 | 8 | 58481 | 104 | 29893885 |
Treatment failure | 21.00 | 10.59 | 22 | 58467 | 34657 | 29859332 |
Mycotic allergy | 20.68 | 10.59 | 9 | 58480 | 168 | 29893821 |
Discharge | 20.35 | 10.59 | 8 | 58481 | 114 | 29893875 |
Chondrocalcinosis | 19.99 | 10.59 | 10 | 58479 | 259 | 29893730 |
Neutrophil count decreased | 19.53 | 10.59 | 33 | 58456 | 42421 | 29851568 |
White blood cell count decreased | 19.41 | 10.59 | 91 | 58398 | 83856 | 29810133 |
Injury | 19.37 | 10.59 | 89 | 58400 | 21642 | 29872347 |
Atrioventricular block second degree | 19.16 | 10.59 | 27 | 58462 | 3113 | 29890876 |
Cerebrovascular accident | 18.72 | 10.59 | 247 | 58242 | 83230 | 29810759 |
Myocardial ischaemia | 18.57 | 10.59 | 75 | 58414 | 17242 | 29876747 |
Acquired haemophilia | 18.47 | 10.59 | 14 | 58475 | 773 | 29893216 |
Electrocardiogram QRS complex shortened | 18.40 | 10.59 | 8 | 58481 | 149 | 29893840 |
Thrombocytopenia | 18.35 | 10.59 | 175 | 58314 | 136869 | 29757120 |
Mite allergy | 18.32 | 10.59 | 9 | 58480 | 224 | 29893765 |
Rheumatoid arthritis | 18.06 | 10.59 | 33 | 58456 | 41164 | 29852825 |
Intentional product use issue | 18.01 | 10.59 | 27 | 58462 | 36413 | 29857576 |
Atrial thrombosis | 17.57 | 10.59 | 20 | 58469 | 1861 | 29892128 |
Malignant neoplasm progression | 17.53 | 10.59 | 77 | 58412 | 72210 | 29821779 |
Nephrogenic systemic fibrosis | 17.52 | 10.59 | 31 | 58458 | 4340 | 29889649 |
Ventricular fibrillation | 17.40 | 10.59 | 67 | 58422 | 15071 | 29878918 |
Pneumocystis jirovecii pneumonia | 17.13 | 10.59 | 6 | 58483 | 17114 | 29876875 |
Ischaemic hepatitis | 17.03 | 10.59 | 18 | 58471 | 1541 | 29892448 |
Eczema infected | 16.97 | 10.59 | 5 | 58484 | 27 | 29893962 |
Gallbladder polyp | 16.70 | 10.59 | 9 | 58480 | 273 | 29893716 |
Palpitations | 16.35 | 10.59 | 117 | 58372 | 33456 | 29860533 |
Hepatic function abnormal | 16.33 | 10.59 | 36 | 58453 | 41909 | 29852080 |
Skin tightness | 16.32 | 10.59 | 20 | 58469 | 2012 | 29891977 |
Spirometry abnormal | 16.23 | 10.59 | 9 | 58480 | 289 | 29893700 |
Toxic optic neuropathy | 15.71 | 10.59 | 12 | 58477 | 670 | 29893319 |
Blood urea increased | 15.65 | 10.59 | 110 | 58379 | 31271 | 29862718 |
Protein urine present | 15.57 | 10.59 | 31 | 58458 | 4744 | 29889245 |
Lymphocyte count decreased | 15.50 | 10.59 | 76 | 58413 | 18979 | 29875010 |
Vitiligo | 15.44 | 10.59 | 12 | 58477 | 688 | 29893301 |
Pacemaker generated rhythm | 15.30 | 10.59 | 5 | 58484 | 40 | 29893949 |
BRASH syndrome | 15.19 | 10.59 | 5 | 58484 | 41 | 29893948 |
Psychotic disorder | 14.98 | 10.59 | 12 | 58477 | 21503 | 29872486 |
Hypoxia | 14.94 | 10.59 | 151 | 58338 | 47703 | 29846286 |
Toxicity to various agents | 14.89 | 10.59 | 452 | 58037 | 176731 | 29717258 |
Pericardial haemorrhage | 14.79 | 10.59 | 23 | 58466 | 2895 | 29891094 |
Mesothelioma | 14.76 | 10.59 | 10 | 58479 | 462 | 29893527 |
Blood pressure immeasurable | 14.64 | 10.59 | 13 | 58476 | 898 | 29893091 |
Cardiac disorder | 14.50 | 10.59 | 130 | 58359 | 39763 | 29854226 |
Blood pressure systolic decreased | 14.49 | 10.59 | 26 | 58463 | 3681 | 29890308 |
Renal injury | 14.38 | 10.59 | 53 | 58436 | 11676 | 29882313 |
Agranulocytosis | 14.35 | 10.59 | 13 | 58476 | 21929 | 29872060 |
Product dose omission issue | 14.03 | 10.59 | 113 | 58376 | 91518 | 29802471 |
Infection | 14.02 | 10.59 | 92 | 58397 | 77982 | 29816007 |
Sinus arrest | 13.92 | 10.59 | 16 | 58473 | 1504 | 29892485 |
Device capturing issue | 13.65 | 10.59 | 3 | 58486 | 3 | 29893986 |
Subacute cutaneous lupus erythematosus | 13.60 | 10.59 | 11 | 58478 | 668 | 29893321 |
Rectal fissure | 13.48 | 10.59 | 8 | 58481 | 293 | 29893696 |
Dust allergy | 13.44 | 10.59 | 9 | 58480 | 408 | 29893581 |
Sepsis | 13.44 | 10.59 | 203 | 58286 | 146192 | 29747797 |
Angina bullosa haemorrhagica | 13.42 | 10.59 | 5 | 58484 | 61 | 29893928 |
Fear | 13.34 | 10.59 | 49 | 58440 | 10776 | 29883213 |
Ventricular tachycardia | 13.31 | 10.59 | 86 | 58403 | 23776 | 29870213 |
Epilepsy | 13.13 | 10.59 | 12 | 58477 | 20157 | 29873832 |
Heart rate irregular | 13.07 | 10.59 | 53 | 58436 | 12206 | 29881783 |
Anuria | 12.97 | 10.59 | 47 | 58442 | 10269 | 29883720 |
Aortic stenosis | 12.86 | 10.59 | 26 | 58463 | 4022 | 29889967 |
Bronchopulmonary aspergillosis | 12.83 | 10.59 | 4 | 58485 | 12280 | 29881709 |
Cardiospasm | 12.79 | 10.59 | 3 | 58486 | 5 | 29893984 |
Eosinophilic pleural effusion | 12.73 | 10.59 | 7 | 58482 | 221 | 29893768 |
Blood pressure inadequately controlled | 12.67 | 10.59 | 20 | 58469 | 2550 | 29891439 |
Mast cell degranulation present | 12.61 | 10.59 | 5 | 58484 | 73 | 29893916 |
Arrhythmia | 12.52 | 10.59 | 109 | 58380 | 33060 | 29860929 |
Antiacetylcholine receptor antibody positive | 12.46 | 10.59 | 4 | 58485 | 30 | 29893959 |
Septic shock | 12.43 | 10.59 | 73 | 58416 | 63534 | 29830455 |
Hyperbilirubinaemia | 12.37 | 10.59 | 9 | 58480 | 16933 | 29877056 |
Encephalopathy | 12.24 | 10.59 | 28 | 58461 | 32177 | 29861812 |
Osteonecrosis of jaw | 12.21 | 10.59 | 11 | 58478 | 18607 | 29875382 |
Product residue present | 12.06 | 10.59 | 20 | 58469 | 2658 | 29891331 |
Drug resistance | 11.93 | 10.59 | 13 | 58476 | 20120 | 29873869 |
Anticoagulation drug level above therapeutic | 11.77 | 10.59 | 16 | 58473 | 1783 | 29892206 |
Abnormal behaviour | 11.70 | 10.59 | 20 | 58469 | 25603 | 29868386 |
Emotional distress | 11.51 | 10.59 | 61 | 58428 | 15704 | 29878285 |
Conjunctivitis allergic | 11.44 | 10.59 | 9 | 58480 | 525 | 29893464 |
Rhabdomyolysis | 11.41 | 10.59 | 181 | 58308 | 63399 | 29830590 |
Labyrinthitis | 11.39 | 10.59 | 11 | 58478 | 846 | 29893143 |
Cardioactive drug level increased | 11.37 | 10.59 | 15 | 58474 | 1624 | 29892365 |
Right ventricular failure | 11.31 | 10.59 | 38 | 58451 | 7998 | 29885991 |
Anhedonia | 11.27 | 10.59 | 39 | 58450 | 8330 | 29885659 |
Dyspnoea exertional | 11.15 | 10.59 | 112 | 58377 | 35318 | 29858671 |
Blood pressure diastolic decreased | 11.11 | 10.59 | 32 | 58457 | 6199 | 29887790 |
Iron binding capacity total increased | 11.11 | 10.59 | 4 | 58485 | 44 | 29893945 |
Arteriospasm coronary | 11.06 | 10.59 | 19 | 58470 | 2599 | 29891390 |
Transaminases increased | 11.00 | 10.59 | 18 | 58471 | 23439 | 29870550 |
Lung adenocarcinoma stage IV | 10.91 | 10.59 | 5 | 58484 | 106 | 29893883 |
Lower gastrointestinal haemorrhage | 10.79 | 10.59 | 37 | 58452 | 7867 | 29886122 |
Unevaluable event | 10.75 | 10.59 | 102 | 58387 | 31683 | 29862306 |
Shock | 10.75 | 10.59 | 79 | 58410 | 22780 | 29871209 |
Infectious mononucleosis | 10.69 | 10.59 | 8 | 58481 | 433 | 29893556 |
Tooth injury | 10.68 | 10.59 | 10 | 58479 | 740 | 29893249 |
Inner ear disorder | 10.62 | 10.59 | 6 | 58483 | 200 | 29893789 |
Source | Code | Description |
---|---|---|
ATC | C05AE03 | CARDIOVASCULAR SYSTEM VASOPROTECTIVES AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Muscle relaxants |
ATC | C08DB01 | CARDIOVASCULAR SYSTEM CALCIUM CHANNEL BLOCKERS SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS Benzothiazepine derivatives |
FDA MoA | N0000000069 | Calcium Channel Antagonists |
FDA EPC | N0000175566 | Calcium Channel Blocker |
MeSH PA | D000959 | Antihypertensive Agents |
MeSH PA | D002121 | Calcium Channel Blockers |
MeSH PA | D000077264 | Calcium-Regulating Hormones and Agents |
MeSH PA | D002317 | Cardiovascular Agents |
MeSH PA | D049990 | Membrane Transport Modulators |
MeSH PA | D014665 | Vasodilator Agents |
CHEBI has role | CHEBI:35620 | vasodilator |
CHEBI has role | CHEBI:35674 | antihypertensive |
CHEBI has role | CHEBI:38215 | calcium channel blockers |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Hypertensive disorder | indication | 38341003 | DOID:10763 |
Atrial fibrillation | indication | 49436004 | DOID:0060224 |
Paroxysmal supraventricular tachycardia | indication | 67198005 | |
Prinzmetal angina | indication | 87343002 | |
Angina pectoris | indication | 194828000 | |
Anal fissure | off-label use | 30037006 | |
Supraventricular arrhythmia | off-label use | 72654001 | |
Diastolic heart failure | off-label use | 418304008 | DOID:9775 |
Hyperkalemia | contraindication | 14140009 | |
Ventricular tachycardia | contraindication | 25569003 | |
Complete atrioventricular block | contraindication | 27885002 | |
Acute cerebrovascular insufficiency | contraindication | 29322000 | |
Sick sinus syndrome | contraindication | 36083008 | DOID:13884 |
Immunosuppression | contraindication | 38013005 | |
Angioedema | contraindication | 41291007 | DOID:1558 |
Low blood pressure | contraindication | 45007003 | |
Bradycardia | contraindication | 48867003 | |
Lown-Ganong-Levine syndrome | contraindication | 55475008 | DOID:13087 |
Aortic valve stenosis | contraindication | 60573004 | DOID:1712 |
Wolff-Parkinson-White pattern | contraindication | 74390002 | DOID:384 |
Transplantation | contraindication | 77465005 | |
Chronic idiopathic constipation | contraindication | 82934008 | |
Hereditary angioneurotic edema | contraindication | 82966003 | DOID:14735 |
Cardiogenic shock | contraindication | 89138009 | |
Hyponatremia | contraindication | 89627008 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Disorder of connective tissue | contraindication | 105969002 | DOID:65 |
Second degree atrioventricular block | contraindication | 195042002 | |
Decompensated cardiac failure | contraindication | 195111005 | |
Hypertrophic cardiomyopathy | contraindication | 233873004 | DOID:11984 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Pregnancy, function | contraindication | 289908002 | |
Renal artery stenosis | contraindication | 302233006 | |
Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
Bone marrow depression | contraindication | 307762000 | |
Left ventricular cardiac dysfunction | contraindication | 429589006 | |
Hemodialysis with High-Flux Membrane | contraindication |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 7.63 | Basic |
None
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
120MG | DILTIAZEM HYDROCHLORIDE | GLENMARK PHARMS LTD | A212317 | March 22, 2021 | RX | CAPSULE, EXTENDED RELEASE | ORAL | Sept. 26, 2021 | COMPETITIVE GENERIC THERAPY |
60MG | DILTIAZEM HYDROCHLORIDE | GLENMARK PHARMS LTD | A212317 | March 22, 2021 | RX | CAPSULE, EXTENDED RELEASE | ORAL | Sept. 26, 2021 | COMPETITIVE GENERIC THERAPY |
90MG | DILTIAZEM HYDROCHLORIDE | GLENMARK PHARMS LTD | A212317 | March 22, 2021 | RX | CAPSULE, EXTENDED RELEASE | ORAL | Sept. 26, 2021 | COMPETITIVE GENERIC THERAPY |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Voltage-dependent L-type calcium channel subunit alpha-1C | Ion channel | BLOCKER | IC50 | 7.32 | WOMBAT-PK | CHEMBL | |||
Voltage-dependent calcium channel gamma-1 subunit | Ion channel | IC50 | 6.10 | WOMBAT-PK | |||||
Cytochrome P450 3A4 | Enzyme | IC50 | 5.74 | DRUG MATRIX | |||||
Voltage-dependent T-type calcium channel subunit alpha-1H | Ion channel | Ki | 4.02 | WOMBAT-PK | |||||
5-hydroxytryptamine receptor 2A | GPCR | Ki | 5.62 | PDSP | |||||
Multidrug resistance protein 1 | Transporter | IC50 | 4.37 | CHEMBL | |||||
Solute carrier family 22 member 1 | Transporter | IC50 | 4.91 | CHEMBL | |||||
Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 4.76 | CHEMBL | |||||
Voltage-dependent L-type calcium channel subunit alpha-1S | Ion channel | Ki | 6.42 | CHEMBL | |||||
Sodium channel alpha subunits; brain (Types I, II, III) | Ion channel | IC50 | 4.35 | CHEMBL | |||||
5-hydroxytryptamine receptor 3A | Ion channel | BLOCKER | IC50 | 4.68 | IUPHAR | ||||
Voltage-dependent L-type calcium channel subunit alpha-1C | Ion channel | IC50 | 4.52 | CHEMBL | |||||
Voltage-gated L-type calcium channel | Ion channel | Ki | 7.80 | CHEMBL | |||||
Voltage-dependent L-type calcium channel subunit alpha-1D | Ion channel | IC50 | 7.34 | CHEMBL | |||||
Voltage-dependent L-type calcium channel subunit alpha-1C | Ion channel | IC50 | 7.27 | CHEMBL | |||||
Potassium voltage-gated channel subfamily C member 1 | Unclassified | BLOCKER | IC50 | 4 | IUPHAR | ||||
Potassium voltage-gated channel subfamily A member 7 | Unclassified | BLOCKER | IC50 | 4.20 | IUPHAR | ||||
5-hydroxytryptamine receptor 3A | Ion channel | BLOCKER | IC50 | 5.26 | IUPHAR | ||||
Voltage-dependent L-type calcium channel subunit alpha-1F | Unclassified | BLOCKER | IC50 | 4 | IUPHAR |
ID | Source |
---|---|
4020128 | VUID |
N0000179650 | NUI |
D00616 | KEGG_DRUG |
33286-22-5 | SECONDARY_CAS_RN |
4018817 | VANDF |
4019722 | VANDF |
4020128 | VANDF |
C0012373 | UMLSCUI |
CHEBI:101278 | CHEBI |
C9F | PDB_CHEM_ID |
39186 | PUBCHEM_CID |
CHEMBL23 | ChEMBL_ID |
CHEMBL1697 | ChEMBL_ID |
CHEMBL1200805 | ChEMBL_ID |
DB00343 | DRUGBANK_ID |
D004110 | MESH_DESCRIPTOR_UI |
2298 | IUPHAR_LIGAND_ID |
3433 | INN_ID |
EE92BBP03H | UNII |
203211 | RXNORM |
1547 | MMSL |
4604 | MMSL |
d00045 | MMSL |
000711 | NDDF |
004514 | NDDF |
007237 | NDDF |
12218006 | SNOMEDCT_US |
372793000 | SNOMEDCT_US |
59941008 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Diltiazem Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-0318 | TABLET, FILM COATED | 30 mg | ORAL | ANDA | 18 sections |
Diltiazem Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-0319 | TABLET, FILM COATED | 60 mg | ORAL | ANDA | 18 sections |
Diltiazem Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-0320 | TABLET, FILM COATED | 90 mg | ORAL | ANDA | 18 sections |
Diltiazem Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-0321 | TABLET, FILM COATED | 120 mg | ORAL | ANDA | 18 sections |
Cardizem | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-0771 | TABLET, COATED | 30 mg | ORAL | NDA | 21 sections |
Cardizem | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-0772 | TABLET, COATED | 60 mg | ORAL | NDA | 21 sections |
Cardizem | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-0791 | TABLET, COATED | 90 mg | ORAL | NDA | 21 sections |
Cardizem | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-0792 | TABLET, COATED | 120 mg | ORAL | NDA | 21 sections |
Cardizem CD | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-0795 | CAPSULE, COATED, EXTENDED RELEASE | 120 mg | ORAL | NDA | 14 sections |
Cardizem CD | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-0796 | CAPSULE, COATED, EXTENDED RELEASE | 180 mg | ORAL | NDA | 14 sections |
Cardizem CD | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-0797 | CAPSULE, COATED, EXTENDED RELEASE | 240 mg | ORAL | NDA | 14 sections |
Cardizem CD | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-0798 | CAPSULE, COATED, EXTENDED RELEASE | 300 mg | ORAL | NDA | 14 sections |
Cardizem CD | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-0799 | CAPSULE, COATED, EXTENDED RELEASE | 360 mg | ORAL | NDA | 14 sections |
Cardizem LA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-2045 | TABLET, EXTENDED RELEASE | 120 mg | ORAL | NDA | 25 sections |
Cardizem LA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-2046 | TABLET, EXTENDED RELEASE | 180 mg | ORAL | NDA | 25 sections |
Cardizem LA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-2047 | TABLET, EXTENDED RELEASE | 240 mg | ORAL | NDA | 25 sections |
Cardizem LA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-2048 | TABLET, EXTENDED RELEASE | 300 mg | ORAL | NDA | 25 sections |
Cardizem LA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-2049 | TABLET, EXTENDED RELEASE | 360 mg | ORAL | NDA | 25 sections |
Cardizem LA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-2050 | TABLET, EXTENDED RELEASE | 420 mg | ORAL | NDA | 25 sections |
TIAZACEXTENDED RELEASE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-2612 | CAPSULE, EXTENDED RELEASE | 120 mg | ORAL | NDA | 23 sections |
TIAZACEXTENDED RELEASE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-2613 | CAPSULE, EXTENDED RELEASE | 180 mg | ORAL | NDA | 23 sections |
TIAZACEXTENDED RELEASE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-2614 | CAPSULE, EXTENDED RELEASE | 240 mg | ORAL | NDA | 23 sections |
TIAZACEXTENDED RELEASE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-2615 | CAPSULE, EXTENDED RELEASE | 300 mg | ORAL | NDA | 23 sections |
TIAZACEXTENDED RELEASE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-2616 | CAPSULE, EXTENDED RELEASE | 360 mg | ORAL | NDA | 23 sections |
TIAZACEXTENDED RELEASE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-2617 | CAPSULE, EXTENDED RELEASE | 420 mg | ORAL | NDA | 23 sections |
Diltiazem Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0228-2918 | CAPSULE, EXTENDED RELEASE | 360 mg | ORAL | ANDA | 20 sections |
Diltiazem Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-6060 | CAPSULE, EXTENDED RELEASE | 60 mg | ORAL | ANDA | 20 sections |
Diltiazem Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-6090 | CAPSULE, EXTENDED RELEASE | 90 mg | ORAL | ANDA | 20 sections |
Diltiazem Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-6120 | CAPSULE, EXTENDED RELEASE | 120 mg | ORAL | ANDA | 20 sections |
Diltiazem Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-1171 | INJECTION, SOLUTION | 5 mg | INTRAVENOUS | ANDA | 24 sections |